Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. It develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. It has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.
์ข
๋ชฉ ์ฝ๋ EVOK
ํ์ฌ ์ด๋ฆEvoke Pharma Inc
์์ฅ์ผSep 25, 2013
CEOD'Onofrio (Matthew J)
์ง์ ์3
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃSep 25
์ฃผ์420 Stevens Avenue
๋์SOLANA BEACH
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ92075
์ ํ18583451494
์น์ฌ์ดํธhttps://evokepharma.com/
์ข
๋ชฉ ์ฝ๋ EVOK
์์ฅ์ผSep 25, 2013
CEOD'Onofrio (Matthew J)
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์